Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 4, keine Gesamtzahl für „effect“
Suchtreffer
Begriffe & Kennungen
Adcirca (previously Tadalafil Lilly) · 4.5 · P-glycoprotein substrates (e.g. digoxin) Tadalafil (40 mg once per day) had no clinically significant effect o
Eintrag öffnenAdcirca (previously Tadalafil Lilly) · 4.5 · Riociguat Preclinical studies showed an additive systemic blood pressure lowering effect when PDE5 inhibitors
Eintrag öffnenAdcirca (previously Tadalafil Lilly) · 4.5 · Riociguat Preclinical trials showed an additive systemic blood pressure lowering effect when PDE5 inhibitors w
Eintrag öffnenAdcirca (previously Tadalafil Lilly) · 4.8 Undesirable effects · 1
Eintrag öffnenAdcirca (previously Tadalafil Lilly) · 4.8 Undesirable effects · 2
Eintrag öffnenAdempas · 4.5 · Effects of other substances on riociguat
Eintrag öffnenAdempas · 4.5 · Effects of other substances on riociguat
Eintrag öffnenAdempas · 4.5 · Effects of riociguat on other substances
Eintrag öffnenAdempas · 4.5 · Effects of riociguat on other substances
Eintrag öffnenAdempas · 4.5 · PDE5 inhibitors Preclinical studies in animal models showed additive systemic blood pressure lowering effect w
Eintrag öffnenAdempas · 4.8 Undesirable effects · 1
Eintrag öffnenAdempas · 4.8 Undesirable effects · 2
Eintrag öffnenAdenuric · 4.8 Undesirable effects · 1
Eintrag öffnenAdenuric · 4.8 Undesirable effects · 2
Eintrag öffnenAdjupanrix (previously Pandemic influenza vaccine (H5N1) (split virion, inactivated, adjuvanted) GlaxoSmithKline Biologicals) · 4.8 Undesirable effects · 1
Eintrag öffnenAdjupanrix (previously Pandemic influenza vaccine (H5N1) (split virion, inactivated, adjuvanted) GlaxoSmithKline Biologicals) · 4.8 · Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.
Eintrag öffnenAdrenergika
Eintrag öffnenAdrovance · 4.8 Undesirable effects · 1
Eintrag öffnenAdstringenzien
Eintrag öffnenAdtralza · 4.5 · The effects of tralokinumab on the pharmacokinetics (PK) of CYP substrates, caffeine (CYP1A2), warfarin (CYP2C
Eintrag öffnen